BrYet

What BrYet does

BrYet US, Inc. is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in Houston, Texas (2450 Holcombe Blvd., Suite 1520), with parallel operations in Australia (first-in-human trial site) and Europe (BrYet Europe under CEO Lorenzo Pradella). The company develops first-in-class oncology therapeutics that target conserved molecular transport phenotypes of lung and liver cancers rather than individual mutations, using a mutationally agnostic, physics-based approach aimed at treating primary and metastatic disease for which curative therapy is currently unavailable.

BrYet's platform rests on two proprietary technologies: Transport Oncophysics, a mathematical framework for predicting biodistribution, pharmacokinetics, toxicokinetics, therapeutic index and efficacy of injected multi- and single-component drugs; and Nanoporous Silicon MicroParticles (NSMP/Si-Plateloid), a transport-enhancing, bio-erodible silicon microparticle formulation that targets the vascular endothelium of the tumor microenvironment. The lead asset ML-016 (iNPG-pDox) combines an amino acid polymer conjugated to doxorubicin with Si-Plateloid, releasing exosome-like 'exosomoids' that are preferentially taken up by cancer cells including treatment-resistant lines. Preclinical data report 40–50% functional cure rates and 50–80% survival beyond five months in lung metastasis models of triple-negative breast cancer and soft-tissue sarcoma.

Commercially, BrYet is pre-revenue and monetizes (and will monetize) through eventual pharmaceutical product sales of ML-016 once regulatory approval is achieved, following a traditional sales-led biopharma go-to-market (clinical development → regulatory approval → commercialization). Patent protection includes U.S. Patent No. 12,390,420 (issued November 2025) plus 50+ issued patents held by scientific founder Dr. Mauro Ferrari, layered on licenses from Houston Methodist Research Institute and University of Texas Health Science Center at Houston. Distribution is currently limited to clinical trial sites (Australia Phase I/II; U.S. under pending IND filed March 2026), with a manufacturing partnership with NerPharMa supporting GMP production for ML-016.

Name

BrYet

Legal name

BrYet US, Inc.

Website

https://bryetpharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

BrYet US, Inc. is a privately held, clinical-stage biotechnology company developing first-in-class oncology therapeutics that target conserved lung and liver cancer transport phenotypes using proprietary Nanoporous Silicon Microparticle (Si-Plateloid) delivery and a Transport Oncophysics design platform, with lead asset ML-016 in Phase I/II trials.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAADAD

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)

Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

SECONDARYHLAGAFAM

In Silico / Computational Toxicology & PK/PD Modeling

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

• Oncology therapeutics development
• Targeted cancer drug delivery
• Nanoporous silicon microparticles
• Transport oncophysics platform
• Metastatic cancer treatment

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: BrYet is a pre-revenue clinical-stage biotechnology company developing first-in-class oncology therapeutics. The company's primary future revenue stream will be from sales of its drug products, specifically ML-016 for treatment of advanced cancers of the lungs and liver. The company is in the process of conducting Phase I/II clinical trials to advance toward regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

BrYet develops first-in-class oncology therapeutics through two proprietary platforms: Transport Oncophysics (a mathematical framework for predicting biodistribution, pharmacokinetics, and therapeutic efficacy of multi-component drugs) and Nanoporous Silicon MicroParticles (NSMP) / Si-Plateloid technology for targeted drug delivery. The company's lead therapeutic candidate ML-016 (iNPG-pDox) combines an amino acid polymer conjugated to doxorubicin with proprietary silicon microparticles designed to target the vascular endothelium of blood vessels in the tumor microenvironment for treatment of advanced primary or metastatic cancers of the lungs and liver.

Product overview

BrYet is a biotechnology company developing first-in-class oncology therapeutics through two proprietary platforms: Transport Oncophysics (a mathematical framework for drug design) and Nanoporous Silicon MicroParticles (NSMP/Si-Plateloid™ formulation technology). The lead product, ML-016 (iNPG-pDox), is an injectable nanoparticle generator combining an amino acid polymer-doxorubicin conjugate with Si-Plateloid technology for targeted treatment of lung and liver cancers.

Differentiator

Problem solved

Functional benefit

Brands

• Si-Plateloid: Proprietary silicon-based platelet-like bio-erodible mesoporous silicon elements technology for targeted drug delivery in cancer treatment
• NSMP (Nanoporous Silicon MicroParticles)
• Transport Oncophysics
• ML-016 (iNPG-pDox)

Products and services

• ML-016 (iNPG-pDox) BrYet's lead oncology therapeutic candidate comprising an amino acid polymer conjugated to doxorubicin with a formulation including proprietary Si-Plateloid silicon microparticles. ML-016 targets the vascular endothelium of blood vessels in the tumor microenvironment, where the amino acid-drug conjugate is released into the tumor and forms exosome-like vesicles (exosomoids) designed for preferential uptake by cancer cells including therapy-resistant cells. It is being developed for treatment of advanced primary or metastatic cancers of the lungs and liver, including metastatic spread from primary cancers originating in other organs or tissue (such as triple-negative breast cancer and soft-tissue sarcoma). Preclinical models demonstrated 40-50% functional cure rates and 50-80% survival beyond five months versus 0% survival in control groups.

Quantifiable outcome

• 40-50% functional cure rate in preclinical metastatic cancer models including treatment-resistant cell lines
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• NerPharMacoreImplementation/ SI/ Consulting Partner · 1 January 2026BrYet entered a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different types of breast cancer. NerPharMa provides manufacturing development services to support the clinical development of ML-016.
• Houston Methodist Research InstitutecoreTechnology or IntegrationBrYet licenses intellectual property from Houston Methodist Research Institute, including patents related to porous silicon manufacturing and targeted drug delivery technologies. Scientific founder Dr. Mauro Ferrari previously served as President and CEO of Houston Methodist Research Institute.
• University of Texas Health Science Center at HoustoncoreTechnology or IntegrationBrYet licenses intellectual property from University of Texas Health Science Center at Houston, contributing to the company's patent portfolio of targeted drug delivery technologies.
• University of WashingtonminorStrategic or Co-development PartnerBrYet has connections with University of Washington where CEO Dr. Mauro Ferrari serves on faculty and where Tong Sun serves as Executive Director of Institute of Translational Health Sciences. The company maintains research partnerships for preclinical studies.
• MD Anderson Cancer CenterminorStrategic or Co-development PartnerBrYet has advisory board connections with MD Anderson Cancer Center. Dr. Apostolia (Lia) Tsimberidou serves as Director of Oncology for BrYet while holding a professorship at MD Anderson. CEO Dr. Mauro Ferrari previously held positions at MD Anderson.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Celsion Corporation: Celsion develops ThermoDox, a heat-activated liposomal doxorubicin for liver cancer and other solid tumors. Similar to BrYet's ML-016 (a doxorubicin-based injectable nanoparticle platform) targeting liver/lung metastases, Celsion is the closest direct comparitor in mechanism and indication.
• Nanobiotix: Nanobiotix develops NBTXR3, a nanoparticle-based radio-enhancer for solid tumors including liver cancer. They share the physics-based, mutation-agnostic nanoparticle mechanism and oncology focus with BrYet's NSMP/Si-Plateloid platform.
• Mersana Therapeutics: Mersana develops antibody-drug conjugates (ADCs) and nanoparticle-based therapeutics for cancer. Both companies operate in oncology with novel drug-delivery approaches targeting solid tumors.
• Arrowhead Pharmaceuticals: Arrowhead develops LNP and polymer-conjugate drug-delivery platforms for siRNA and other therapeutics. BrYet's Transport Oncophysics and Si-Plateloid platforms share the polymer/LNP-style nanoparticle delivery category. BrYet's CEO Dr. Mauro Ferrari sits on Arrowhead's board.
• BIND Therapeutics: BIND developed Accurins, targeted polymeric nanoparticles for cancer therapy with a similar nanoparticle-based targeted drug delivery approach to BrYet's NSMP/Si-Plateloid.

Emerging players

• Codiak BioSciences: Codiak developed engineered exosome therapeutics for cancer (engEx platform). BrYet's ML-016 also produces exosome-like 'exosomoids' that deliver doxorubicin to cancer cells, making their delivery biology directly analogous.
• Intensity Therapeutics: Intensity Therapeutics develops intratumoral drug-delivery platforms designed to bypass resistance mechanisms in solid tumors. Their direct-injection mechanism targeting tumor vasculature shares conceptual DNA with BrYet's ML-016.
• Ziopharm Oncology: Ziopharm develops cytokine-based and gene-therapy oncology treatments. They are a relevant clinical-stage oncology peer in the lung and liver metastasis space with innovative delivery approaches.
• Exicure: Exicure developed spherical nucleic acid (SNA) nanoparticle platforms for oncology. Their nanoparticle delivery approach to cancer targets overlaps with BrYet's preclinical-stage nanoparticle strategy.

Broad incumbents

• Eli Lilly (Loxo Oncology): Lilly's Loxo unit develops precision oncology therapeutics including for lung and liver cancers. They represent the incumbent standard of care competitor and potential BD partner/acquirer for a niche oncology asset like ML-016.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/BrYetUS
• LinkedInlinkedin.com/company/bryet-us-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrYet